WO2002010164A3 - Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers - Google Patents

Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers Download PDF

Info

Publication number
WO2002010164A3
WO2002010164A3 PCT/US2001/023804 US0123804W WO0210164A3 WO 2002010164 A3 WO2002010164 A3 WO 2002010164A3 US 0123804 W US0123804 W US 0123804W WO 0210164 A3 WO0210164 A3 WO 0210164A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydropyrrolopyridine
dihydronaphthyridine
derivated
compounds
potassium channel
Prior art date
Application number
PCT/US2001/023804
Other versions
WO2002010164A2 (en
Inventor
Konstantinos Agrios
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to EP01963751A priority Critical patent/EP1307453A2/en
Priority to CA002385908A priority patent/CA2385908A1/en
Priority to JP2002515893A priority patent/JP2004505081A/en
Publication of WO2002010164A2 publication Critical patent/WO2002010164A2/en
Publication of WO2002010164A3 publication Critical patent/WO2002010164A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/US2001/023804 2000-08-02 2001-07-27 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers WO2002010164A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01963751A EP1307453A2 (en) 2000-08-02 2001-07-27 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
CA002385908A CA2385908A1 (en) 2000-08-02 2001-07-27 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
JP2002515893A JP2004505081A (en) 2000-08-02 2001-07-27 Dihydronaphthyridine potassium channel opener

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63119300A 2000-08-02 2000-08-02
US09/631,193 2000-08-02

Publications (2)

Publication Number Publication Date
WO2002010164A2 WO2002010164A2 (en) 2002-02-07
WO2002010164A3 true WO2002010164A3 (en) 2002-04-25

Family

ID=24530165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023804 WO2002010164A2 (en) 2000-08-02 2001-07-27 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers

Country Status (4)

Country Link
EP (1) EP1307453A2 (en)
JP (1) JP2004505081A (en)
CA (1) CA2385908A1 (en)
WO (1) WO2002010164A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2006232819A (en) * 2005-01-25 2006-09-07 Takeda Chem Ind Ltd Method for producing cyanodihydropyridine compound
DE102006026585A1 (en) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use
DE102006026583A1 (en) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituted hetero-bicyclic compounds and their use
DE102007009494A1 (en) 2007-02-27 2008-08-28 Bayer Healthcare Ag New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke
CN101619041B (en) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 Method for synthesizing diketo nitrogen-containing compound and intermediates thereof
WO2010094405A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
CN109721536B (en) * 2017-10-27 2020-11-24 广东东阳光药业有限公司 Phenyl-substituted fused tricyclic compounds and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130041A1 (en) * 1981-07-30 1983-02-17 Bayer Ag, 5090 Leverkusen Dihydropyridines having a positive inotropic effect, novel compounds, their use in medicaments, and processes for their preparation
EP0111455A2 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Unsaturated lactones
EP0111453A1 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Amide derivatives
EP0133530A2 (en) * 1983-07-30 1985-02-27 Gödecke Aktiengesellschaft 1,6-Naphthyridinone derivatives, process for their preparation, and medicaments containing them
US4567268A (en) * 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130041A1 (en) * 1981-07-30 1983-02-17 Bayer Ag, 5090 Leverkusen Dihydropyridines having a positive inotropic effect, novel compounds, their use in medicaments, and processes for their preparation
EP0111455A2 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Unsaturated lactones
EP0111453A1 (en) * 1982-12-10 1984-06-20 Ciba-Geigy Ag Amide derivatives
EP0133530A2 (en) * 1983-07-30 1985-02-27 Gödecke Aktiengesellschaft 1,6-Naphthyridinone derivatives, process for their preparation, and medicaments containing them
US4567268A (en) * 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. D. MAYA ET AL.: "Effects of 3-chloro-phenyl-1,4-dihydropyridine derivatives on Trypanosome cruzi epimastigotes", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY PART C, vol. 125, no. 1, 2000, pages 103 - 109, XP002188922 *

Also Published As

Publication number Publication date
EP1307453A2 (en) 2003-05-07
JP2004505081A (en) 2004-02-19
WO2002010164A2 (en) 2002-02-07
CA2385908A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
GB2390091B (en) Bisarylamines as potassium channel openers
AU5557700A (en) New uses for potassium channel openers
AU2001253535A1 (en) Channel dancer
IL156312A0 (en) Ortho-substituted nitrogen-containing bisaryl compounds uses as potassium channel inhibitors
AU2001276031A1 (en) Branded channel
AU2003294441A8 (en) 1-aryl-2-hydroxyethyl amides as potassium channel openers
AU7476301A (en) Novel compounds
EP1363884A4 (en) Pyridine-substituted benzanilides as potassium ion channel openers
EP1276755A4 (en) Novel compounds
EP1317538A4 (en) Novel compounds
GB0020532D0 (en) Channel member
EP1255771A4 (en) Novel compounds
EP1292617A4 (en) Novel compounds
EP1421936A4 (en) Potassium channel opener
AU2003295781A8 (en) Arylcyclopropylcarboxylic amides as potassium channel openers
AU2002249809A1 (en) Potassium channel inhibitors
AU7476401A (en) Novel compounds
EP1276866A4 (en) Novel compounds
WO2002010164A3 (en) Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
PL343883A1 (en) Cyclopentanone dihydropyridine compounds useful as potassium channel openers
EP1299530A4 (en) Novel compounds
IL156352A0 (en) Sodium channel moddulators derived from 2-piperidylimidazoles
EP1347050A4 (en) Novel potassium channel
EP1347049A4 (en) Novel potassium channel
AU2002306716A1 (en) Bisarylamines as potassium channel openers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2385908

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 515893

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003351

Country of ref document: MX

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001963751

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2001963751

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001963751

Country of ref document: EP